Skip to main content
Clinical Trials/NCT05329077
NCT05329077
Completed
N/A

A Study to Assess the Safety and Efficacy of Pulsenmore ES Home Ultrasound Device in Pregnant Women

PulseNmore4 sites in 1 country188 target enrollmentApril 14, 2022
ConditionsPerinatal Care

Overview

Phase
N/A
Intervention
Not specified
Conditions
Perinatal Care
Sponsor
PulseNmore
Enrollment
188
Locations
4
Primary Endpoint
Comparison of device derived presence or absence of fetal cardiac activity to ground truth
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

This is a multicenter, prospective, investigational device study designed to evaluate:

The safety, feasibility, and accuracy of the device, when used by pregnant individuals

Registry
clinicaltrials.gov
Start Date
April 14, 2022
End Date
November 11, 2023
Last Updated
2 years ago
Study Type
Interventional
Study Design
Single Group
Sex
Female

Investigators

Sponsor
PulseNmore
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Singleton gestation.
  • Gestational age \>14 weeks with a prior scan demonstrating fetal viability and confirming dates.
  • English or Spanish speaking.
  • Ability to understand and sign the informed consent (available in English and Spanish).
  • Ability to read and understand instructions that are required for equipment use (instructions available in both languages).

Exclusion Criteria

  • Multiple gestations.
  • Known fetal and genetic anomalies.
  • Subjects with skin problems in the abdominal area (such as wounds, cuts in the skin, and skin rash).
  • Subjects allergic to the ultrasound probe materials.
  • Non-English/ non-Spanish speaking.
  • Unable to provide consent.

Outcomes

Primary Outcomes

Comparison of device derived presence or absence of fetal cardiac activity to ground truth

Time Frame: Test to be conducted during week 14-38 of pregnancy

The presence or absence of device derived fetal cardiac activity would be matched with the presence or absence of fetal cardiac activity derived by the ground truth (in-clinic ultrasound scan)

Comparison of device derived amniotic fluid level status, normal or abnormal, to ground truth

Time Frame: Test to be conducted during week 14-38 of pregnancy

Comparison of device derived amniotic fluid level status, normal or abnormal, (measured by maximal vertical pocket in cm) would be matched with amniotic fluid level status derived from the ground truth (in-clinic ultrasound scan)

Secondary Outcomes

  • Ability to detect fetal movement from device derived input will be compared to the ground truth(Test to be conducted during week 14-38 of pregnancy)
  • Ability to assess placental location from device derived input will be compared to the ground truth(Test to be conducted during week 14-38 of pregnancy)
  • Ability to detect fetal breathing from device derived input will be compared to the ground truth(Test to be conducted during week >27-38 of pregnancy)
  • Ability to assess fetal presentation from device derived input will be compared to the ground truth(Test to be conducted during week 14-38 of pregnancy)

Study Sites (4)

Loading locations...

Similar Trials